Amgen Inc, 1120 Veterans Blvd., South San Francisco, CA 94080, USA.
Bioorg Med Chem Lett. 2012 Oct 1;22(19):6218-23. doi: 10.1016/j.bmcl.2012.08.015. Epub 2012 Aug 10.
GPR142 is a novel GPCR that is predominantly expressed in pancreatic β-cells. GPR142 agonists potentiate glucose-dependent insulin secretion, and therefore can reduce the risk of hypoglycemia. Optimization of our lead pyridinone-phenylalanine series led to a proof-of-concept compound 22, which showed in vivo efficacy in mice with dose-dependent increase in insulin secretion and a decrease in glucose levels.
GPR142 是一种新型的 G 蛋白偶联受体,主要在胰腺 β 细胞中表达。GPR142 激动剂可增强葡萄糖依赖性胰岛素分泌,因此可以降低低血糖的风险。我们对先导吡啶酮-苯丙氨酸系列进行了优化,得到了一个概念验证化合物 22,该化合物在小鼠体内具有剂量依赖性增加胰岛素分泌和降低血糖水平的作用。